Manage episode 495665864 series 3645668
Sarepta Therapeutics (SRPT) shares are getting crushed after a series of analyst downgrades on the heels of an FDA request to stop its Elevidys treatment. Rachel Dashiell diagnoses the biotech company's technical patterns taking shape on the chart. For the short-term chart, she sees resistance around $17 amid a strong downtrend. On the longer 15-year timeframe, Rachel says the 200-day moving average has acted as long term support for about 7 years around the $120 point.
======== Schwab Network ========
Empowering every investor and trader, every market day.
Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribe
Download the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185
Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7
Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watch
Watch on Vizio - https://www.vizio.com/en/watchfreeplus-explore
Watch on DistroTV - https://www.distro.tv/live/schwab-network/
Follow us on X – / schwabnetwork
Follow us on Facebook – / schwabnetwork
Follow us on LinkedIn - / schwab-network
About Schwab Network - https://schwabnetwork.com/about
6136 episodes